Banner - NPPA Connect
NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Joshua Burshtein, MD

Advertisement

Articles by Joshua Burshtein, MD

Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

ByJoshua Burshtein, MD
December 17th 2025

Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.

Advertisement

Latest Updated Articles

  • Highlighting Major Breakthroughs for Atopic Dermatitis  and Psoriasis in 2025
    Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

    Published: December 17th 2025 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

2

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

3

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

4

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

5

Introducing Dermatology Times NP/PA Connect

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us